Skip to main content

Table 3 Positron emission tomography patterns in participants receiving different vaccines

From: Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on 18F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine

 

AZ group (n = 263)

M group (n = 310)

p-value

HLN

38 (14%)

74 (24%)

0.006

 ≤ 4 weeks

21/92 (23%)

39/92 (42%)

0.008

 > 4 weeks

17/171 (10%)

35/218 (16%)

0.11

p-valuea

0.008

 < 0.0001

 

SUVmax of HLN

3.0 ± 1.3

3.0 ± 1.3

0.92

Vaccination dose

 First dose

32/204 (16%)

60/271 (22%)

0.10

 Second dose

6/59 (10%)

14/39 (36%)

0.005

p-value

0.39

0.09

 

DL

27 (10%)

25 (8%)

0.44

 ≤ 4 weeks

23/92 (25%)

21/92 (23%)

0.86

 > 4 weeks

4/171 (2%)

4/218 (2%)

0.73

p-valuea

 < 0.0001

 < 0.0001

 

SUVmax of DL

2.2 ± 0.9

1.9 ± 0.6

0.08

  1. a Comparison between the first 4 weeks and beyond 4 weeks after vaccination
  2. AZ, Oxford-AstraZeneca; M, Moderna; HLN, hypermetabolic lymphadenopathy; DL, deltoid muscle uptake
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us